Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

3073.pdf (2.88 MB)

Document type

Article

Version

Accepted version

Publication date

2017-07-01

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/114916

Alzheimer´s Disease-associated Aβ42 Peptide: Expression and Purification for NMR Structural Studies

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

http://dx.doi.org/10.2174/2212796811666170206113722

Abstract

Background: The aggregation of the amyloid-beta peptide (Aβ) in the brain is strongly associated with Alzheimer´s disease (AD). However, the heterogeneous and transient nature of this process has prevented identification of the exact molecular form of Aβ responsible for the neurotoxicity observed in this disease. Therefore, characterizing Aβ aggregation is of utmost importance in the field of AD. Nuclear magnetic resonance spectroscopy (NMR) is a technique that holds great potential to achieve this goal. However, it requires the use of specific labels introduced through recombinant expression of Aβ. Objective: In this paper, we report on a straightforward expression and purification protocol to obtain [U-15N] and [U-2H,13C,15N] Aβ42. Method: Aβ42 is expressed fused to Small Ubiquitin-like Modifier (SUMO) protein, which prevents Aβ42 aggregation. Results: The solubilizing capacity of SUMO has allowed us to design a purification protocol involving immobilized metal affinity chromatography (IMAC), a desalting step, and two size exclusion chromatography (SEC) purifications. Conclusion: This approach, which does not require the use of costly and time-consuming reversed phase high performance liquid chromatography (RP-HPLC), offers a much straightforward strategy to those previously described to obtain [U-15N] Aβ42 and it is the first protocol through which to achieve [U-2H,13C,15N] Aβ42. The peptides obtained are of high purity and have the required isotope enrichment to support NMR-based structural studies.

Subject

Malaltia d'Alzheimer

Subject (English)

Alzheimer's disease

Citation

Collections

Articles publicats en revistes (Institut de Recerca Biomèdica (IRB Barcelona))

Citation

SERRA BATISTE, Montserrat, et al. Alzheimer´s Disease-associated Aβ42 Peptide: Expression and Purification for NMR Structural Studies. Current Chemical Biology. 2017. ISSN 2212-7968. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/114916

Export metadata

JSON - METS

Share record